Navigation Links
Oculus Innovative Sciences to Present at 4th Annual BIO InvestorForum Conference

PETALUMA, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Oculus Innovative Sciences, Inc. (Nasdaq: OCLS) announced today that the company will be presenting at the 4th Annual BIO InvestorForum Conference to be held October 9-11, 2007 at the Palace Hotel of San Francisco. The company's president and chief executive officer, Hoji Alimi, is scheduled to present an overview of the company, its clinical programs and the most recent quarter on Thursday, October 11 at 1:30 p.m. PDT (4:30 p.m. EDT) in the Sea Cliff room. For more information on this event please visit:

To access a live audio and visual webcast of Mr. Alimi's presentation, please log on to Oculus Innovative Sciences' website at approximately 30 minutes prior to the presentation in order to register and download any necessary software. The webcast will be available for 30 days at this website.

About Oculus

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn(R) Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a controlled slow-release solution containing active chlorine and other gases resulting in a biocompatible technology to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores. The technology has demonstrated significant wound healing in chronic and acute wounds. It has been commercialized outside of the U.S. for the treatment of infected wounds. It is currently under evaluation for the treatment of mildly infected diabetic ulcers in the U.S.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe, Latin America and Japan through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V., Oculus Technologies of Mexico, S.A. de C.V. and Oculus Japan K.K. Oculus' website is

Oculus Innovative Sciences, Inc. The Ruth Group

Dan McFadden Sara Ephraim (investors)

Director of Public and (646) 536-7002

Investor Relations

(425) 753-2105 Jason Rando/

Janine McCargo (media)

(646) 536-7025 / 7033

SOURCE Oculus Innovative Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
2. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
3. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
4. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
7. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
8. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
9. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
10. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
11. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... -- ) has announced the ... Viscosity Drugs" report to their offering. ... of the "Self Administration of High Viscosity ... Research and Markets ( ) has ... of High Viscosity Drugs" report to their ...
(Date:11/25/2015)... 2015 ... "Global Brain Monitoring Devices Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 25, 2015 , ... The holiday season is jam-packed with ... palates of attendees is of the utmost importance. Whether you are cooking at ... these recipes a try this holiday season. , Turkey Croquettes , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the Ageless ... treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, ... without the need for surgery, prescription pills, or topical foams. , “Capillus272™ Pro ...
(Date:11/25/2015)... ... 2015 , ... According to an article published November 10th by ... heralded as a breakthrough for performing hernia repairs. The article explains that the biggest ... that it can greatly reduce the pain that a patient might otherwise experience after ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, AZ) - Today, ... specializing in both surgical and non-surgical treatments, announced the expansion of his private ... Plastic Surgery. , Highly trained and nationally recognized for his natural approach, ...
Breaking Medicine News(10 mins):